Diagnosis of Hepatocellular Carcinoma Using Gd-EOB-DTPA MR Imaging

Magn Reson Med Sci. 2022 Mar 1;21(1):168-181. doi: 10.2463/mrms.rev.2021-0031. Epub 2021 Aug 21.

Abstract

Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA; Gadoxetic acid; Gadoxetate disodium) is a hepatocyte-specific MR contrast agent. It acts as an extracellular contrast agent in the early phase after intravenous injection, and then is taken up by hepatocytes later. Using this contrast agent, we can evaluate the hemodynamics of the liver and liver tumors, and can therefore improve the detection and characterization of hepatocellular carcinoma (HCC). Gd-EOB-DTPA helps in the more accurate detection of hypervascular HCC than by other agents. In addition, Gd-EOB-DTPA can detect hypovascular HCC, which is an early stage of the multi-stage carcinogenesis, with a low signal in the hepatobiliary phase. In addition to tumor detection and characterization, Gd-EOB-DTPA contrast-enhanced MR imaging can be applied for liver function evaluation and prognoses evaluation. Thus, Gd-EOB-DTPA plays an important role in the diagnosis of HCC. However, we have to employ optimal imaging techniques to improve the diagnostic ability. In this review, we aimed to discuss the characteristics of the contrast media, optimal imaging techniques, diagnosis, and applications.

Keywords: gadoxetic acid; hepatocellular carcinoma; liver; magnetic resonance; xetate disodium.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular* / diagnostic imaging
  • Contrast Media
  • Gadolinium DTPA
  • Humans
  • Liver Neoplasms* / diagnostic imaging
  • Magnetic Resonance Imaging / methods

Substances

  • Contrast Media
  • gadolinium ethoxybenzyl DTPA
  • Gadolinium DTPA